BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:River 2 Renal readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies River 2 Renal's drugs run\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07625553-635@assetmemo.bio
DTSTAMP:20261121T010123Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:R2R01: Phase 2 readout est. (NCT07625553)
DESCRIPTION:R2R01\, phase 2.\nStudy: Study of the Relaxin Agonist R2R01 in 
 Patients at High Risk for Cardiac Surgery Associated- Acute Kidney Injury\
 nEstimated primary completion: 1 April 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/r2r01#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07625553
URL:https://assetmemo.bio/drug/r2r01#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
